Barchart.com
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

A-Mark Precious Meta (AMRK)

A-Mark Precious Meta (AMRK)
29.11 -0.25 (-0.85%) 14:43 ET [NASDAQ]
29.04 x 600 29.13 x 51
Realtime by (Cboe BZX)
29.04 x 600 29.13 x 51
Realtime 28.31 -1.05 (-3.58%) 09:17 ET
Quote Overview for Thu, Mar 20th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Day Low
29.01
Day High
29.89
Open 29.16
Previous Close 29.36 29.36
Volume 96,017 96,017
Avg Vol 226,123 226,123
Stochastic %K 92.49% 92.49%
Weighted Alpha -7.85 -7.85
5-Day Change +1.90 (+6.96%) +1.90 (+6.96%)
52-Week Range 25.01 - 47.39 25.01 - 47.39
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
 Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 675,838
  • Shares Outstanding, K 23,019
  • Annual Sales, $ 9,699 M
  • Annual Income, $ 68,550 K
  • EBIT $ 68 M
  • EBITDA $ 82 M
  • 60-Month Beta 0.07
  • Price/Sales 0.07
  • Price/Cash Flow 7.00
  • Price/Book 1.00

Options Overview Details

View History
  • Implied Volatility 41.43% ( -2.37%)
  • Historical Volatility 29.24%
  • IV Percentile 20%
  • IV Rank 32.36%
  • IV High 66.76% on 04/22/24
  • IV Low 29.31% on 06/05/24
  • Put/Call Vol Ratio 0.07
  • Today's Volume 263
  • Volume Avg (30-Day) 299
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 11,611
  • Open Int (30-Day) 11,436

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.60
  • Number of Estimates 2
  • High Estimate 0.78
  • Low Estimate 0.42
  • Prior Year 0.49
  • Growth Rate Est. (year over year) +22.45%
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.
Get delivered to your inbox for FREE:
Sign Up.

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.72 +13.53%
on 03/04/25
Period Open: 27.45
29.89 -2.31%
on 03/20/25
+1.75 (+6.38%)
since 02/20/25
3-Month
25.01 +16.75%
on 12/24/24
Period Open: 25.79
30.17 -3.22%
on 02/07/25
+3.41 (+13.22%)
since 12/20/24
52-Week
25.01 +16.75%
on 12/24/24
Period Open: 28.78
47.39 -38.38%
on 09/16/24
+0.42 (+1.46%)
since 03/20/24

Most Recent Stories

More News
Bear of the Day: A-Mark Precious Metals (AMRK)
Bear of the Day: A-Mark Precious Metals (AMRK) Zacks Investment Research - Thu Mar 13, 5:12AM CDT

A-Mark Precious Metals AMRK is a full-service precious metals trading company offering various products and services. Analysts have taken a bearish stance on the company’s outlook, landing the stock...

AMRK : 29.11 (-0.85%)
A-Mark Continues Expansion into the Bullion Adjacent Collectible Coin Market by Acquiring Stack’s Bowers Galleries, AMS Holding, LLC, and Pinehurst Coin Exchange, Inc. GlobeNewswire - Mon Mar 10, 7:00AM CDT

AMRK : 29.11 (-0.85%)
Bear of the Day: AMark Precious Metals (AMRK)
Bear of the Day: AMark Precious Metals (AMRK) Zacks Investment Research - Thu Feb 13, 4:08AM CST

Disappointing results for A-Mark Precious Metals' AMRK fiscal second quarter makes its stock one to avoid after releasing its Q2 report last Friday.Operating as a full-service precious metals trading...

AMRK : 29.11 (-0.85%)
A-Mark: Fiscal Q2 Earnings Snapshot AP - Thu Feb 6, 3:53PM CST

A-Mark: Fiscal Q2 Earnings Snapshot

AMRK : 29.11 (-0.85%)
A-Mark Precious Metals Reports Fiscal Second Quarter 2025 Results GlobeNewswire - Thu Feb 6, 3:05PM CST

AMRK : 29.11 (-0.85%)
A-Mark Expands Product Portfolio into Collectibles by Acquiring the Parent of Stack’s Bowers Galleries, A Leading Global Rare Coin Auction House and Dealer GlobeNewswire - Mon Feb 3, 7:00AM CST

AMRK : 29.11 (-0.85%)
A-Mark Precious Metals Changes Fiscal Second Quarter Earnings Call to Thursday, February 6th at 4:30 p.m. ET GlobeNewswire - Tue Jan 21, 3:05PM CST

AMRK : 29.11 (-0.85%)
A-Mark Precious Metals Sets Fiscal Second Quarter Earnings Call for Friday, February 7th at 4:30 p.m. ET GlobeNewswire - Fri Jan 17, 7:00AM CST

AMRK : 29.11 (-0.85%)
A-Mark Precious Metals Announces Quarterly Cash Dividend GlobeNewswire - Fri Jan 3, 7:00AM CST

AMRK : 29.11 (-0.85%)
Implied Volatility Surging for A-Mark Precious Metals (AMRK) Stock Options
Implied Volatility Surging for A-Mark Precious Metals (AMRK) Stock Options Zacks Investment Research - Mon Nov 25, 2024

Investors in A-Mark Precious Metals, Inc. AMRK need to pay close attention to the stock based on moves in the options market lately. That is because the Dec. 20, 2024 $20.00 Call had some of the highest...

AMRK : 29.11 (-0.85%)
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS PR Newswire - Mon Nov 14, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET PR Newswire - Fri Sep 23, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA PR Newswire - Wed Sep 7, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
BINV : 34.07 (-1.62%)
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS PR Newswire - Fri Aug 12, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022 PR Newswire - Fri Aug 5, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION PR Newswire - Fri Jul 8, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China ACCESS Newswire - Fri Dec 10, 2021

LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...

BINV : 34.07 (-1.62%)
CASI : 2.36 (+2.61%)
Stocks-Money-Rates - Chart with Stocks and Commodities
Pre-Market Brief: Stocks See Support from Dovish Chinese Policy News Barchart - Mon Nov 22, 2021

Morning Markets Dec S&P 500 futures this morning are up by +0.21%. Stocks are seeing support from a rally in Chinese stocks today on signs that China’s central bank may soon ease monetary policy. In...

MRNA : 32.93 (-1.17%)
VG : 11.65 (+4.02%)
GFS : 37.80 (-2.05%)
CASI : 2.36 (+2.61%)
ASTR : 0.5390 (-2.00%)
ATVI : 94.42 (-0.05%)
PGNY : 21.74 (+0.14%)
AUPH : 8.34 (-0.36%)
CASI Pharmaceuti­­­cals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization PR Newswire - Mon Oct 25, 2021

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026 FinancialNewsMedia - Tue Aug 24, 2021

Palm Beach, FL – August 24, 2021 – FinancialNewsMedia.com News Commentary – Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense...

QBIO : 0.0001 (unch)
ABVC : 0.6659 (+0.89%)
TRIL : 18.44 (+2.62%)
CASI : 2.36 (+2.61%)
SESN : 12.5760 (+7.29%)
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS PR Newswire - Mon Nov 14, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET PR Newswire - Fri Sep 23, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA PR Newswire - Wed Sep 7, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
BINV : 34.07 (-1.62%)
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS PR Newswire - Fri Aug 12, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022 PR Newswire - Fri Aug 5, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION PR Newswire - Fri Jul 8, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China ACCESS Newswire - Fri Dec 10, 2021

LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...

BINV : 34.07 (-1.62%)
CASI : 2.36 (+2.61%)
Stocks-Money-Rates - Chart with Stocks and Commodities
Pre-Market Brief: Stocks See Support from Dovish Chinese Policy News Barchart - Mon Nov 22, 2021

Morning Markets Dec S&P 500 futures this morning are up by +0.21%. Stocks are seeing support from a rally in Chinese stocks today on signs that China’s central bank may soon ease monetary policy. In...

MRNA : 32.93 (-1.17%)
VG : 11.65 (+4.02%)
GFS : 37.80 (-2.05%)
CASI : 2.36 (+2.61%)
ASTR : 0.5390 (-2.00%)
ATVI : 94.42 (-0.05%)
PGNY : 21.74 (+0.14%)
AUPH : 8.34 (-0.36%)
CASI Pharmaceuti­­­cals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization PR Newswire - Mon Oct 25, 2021

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026 FinancialNewsMedia - Tue Aug 24, 2021

Palm Beach, FL – August 24, 2021 – FinancialNewsMedia.com News Commentary – Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense...

QBIO : 0.0001 (unch)
ABVC : 0.6659 (+0.89%)
TRIL : 18.44 (+2.62%)
CASI : 2.36 (+2.61%)
SESN : 12.5760 (+7.29%)
More news for this symbol

Business Summary

A-Mark Precious Metals, Inc. operates as a full service precious metals trading company offering a wide array of products and services. The Company's products include gold, silver, platinum and palladium for storage and delivery in the form of coins, bars, wafers and grain. Its services include financing,...

See More

AMRK Related ETFs

Managed Assets
Percent
Symbol %Holdings 3M %Chg
AMRK +13.22%
A-Mark Precious Meta
IWM 0.02% -7.39%
Russell 2000 Ishares ETF
IWN 0.04% -5.76%
Russell 2000 Value Ishares ETF
VTI 0% -4.94%
Total Stock Market ETF Vanguard
DFAT 0.04% -5.08%
Dimensional U.S. Targeted Value ETF
PRFZ 0.16% -7.58%
FTSE RAFI US 1500 Small/Mid Invesco ETF
Symbol %Holdings 3M %Chg
AMRK +13.22%
A-Mark Precious Meta
DEEP 1.16% -6.20%
Deep Value ETF
BSVO 0.16% -7.41%
Ea Bridgeway Omni Small-Cap Value ETF
PRFZ 0.16% -7.58%
FTSE RAFI US 1500 Small/Mid Invesco ETF
IWC 0.13% -9.76%
Micro-Cap Ishares ETF
IWN 0.04% -5.76%
Russell 2000 Value Ishares ETF

AMRK Related stocks

Symbol Last 3M %Chg
AMRK 29.11 +13.22%
A-Mark Precious Meta
CTHR 1.0000 -33.79%
Charles & Colvard

Compare Symbols

Key Turning Points

Daily
52-Week
3rd Resistance Point 30.52
2nd Resistance Point 30.01
1st Resistance Point 29.68
Last Price 29.11
1st Support Level 28.84
2nd Support Level 28.33
3rd Support Level 28.00

See More

52-Week High 47.39
Fibonacci 61.8% 38.84
Fibonacci 50% 36.20
Fibonacci 38.2% 33.56
Last Price 29.11
52-Week Low 25.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals
Wed, Mar 26, 2025 5:00 PM UTC
Reserve Your Spot